What is the survival rate for high-risk multiple myeloma

Survival Rates for High-Risk Multiple Myeloma

I appreciate this important question. I need to be direct with you: the NCCN Guidelines for Patients materials I have access to do not provide specific survival rate statistics for high-risk multiple myeloma. This is an important limitation to acknowledge.

What the Guidelines DO Tell Us About High-Risk Myeloma

According to the NCCN Guidelines for Patients: Multiple Myeloma, high-risk myeloma is identified by specific genetic abnormalities found through testing. These include:

High-risk features:

• Extra copies (duplication/amplification) or deletion of parts of chromosome 1
• Deletion of part or all of chromosome 17
• Mutations in chromosome 17
• Translocations (swapping) between chromosomes 4 and 14, 14 and 16, or 14 and 20
• Translocations within the MYC gene
• High levels of beta-2-microglobulin

The guidelines note that high-risk myeloma is associated with disease that "grows faster, is harder to treat, and relapses earlier" compared to standard-risk disease.

Why I Can't Give You Specific Numbers

Survival statistics require detailed clinical trial data and population studies that go beyond the patient education guidelines I'm referencing. These numbers also change as new treatments become available.

What You Should Do

I strongly recommend asking your oncology team these specific questions:

1. "Based on my specific genetic test results, what is my risk category?"
2. "What are the survival statistics for patients with my particular genetic abnormalities?"
3. "How do newer treatments affect survival outcomes for high-risk myeloma?"
4. "What clinical trials might be appropriate for my situation?"

For detailed survival statistics, you can also consult:

• National Cancer Institute (NCI) at cancer.gov - they maintain current survival data
• American Cancer Society - provides updated statistics by risk category
• Your cancer center's tumor registry, which may have institution-specific outcomes

The Encouraging Context

The NCCN Guidelines emphasize that "new treatments have resulted in more long-term survivors of myeloma now than ever before" and that "for an increasing number of people, myeloma is a chronic medical problem they learn to live with rather than a disease that they die from."

This is particularly relevant for high-risk patients, as newer targeted therapies, immunotherapies, and CAR T-cell treatments have expanded treatment options significantly.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.